Evdokia Anagnostou1,2. 1. Holland Bloorview Kids Rehabilitation Hospital. 2. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin). However, there is no evidence yet to support the routine use of pharmaceuticals for the treatment of core symptom domains. Challenges in the field include biological heterogeneity within ASD, lack of biomarkers that clarify biological heterogeneity or predict response to treatment, lack of data across the lifespan, and suboptimal outcome measures. SUMMARY: Several compounds have evidence for the treatment of co-occurring symptoms in children and youth with ASD, although pharmacological interventions for core symptoms are still lacking. Identifying the various biologies underling ASD and developing biomarkers that stratify biologically homogeneous populations are both necessary to realize the promise of precision medicine in ASD.
PURPOSE OF REVIEW: The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin). However, there is no evidence yet to support the routine use of pharmaceuticals for the treatment of core symptom domains. Challenges in the field include biological heterogeneity within ASD, lack of biomarkers that clarify biological heterogeneity or predict response to treatment, lack of data across the lifespan, and suboptimal outcome measures. SUMMARY: Several compounds have evidence for the treatment of co-occurring symptoms in children and youth with ASD, although pharmacological interventions for core symptoms are still lacking. Identifying the various biologies underling ASD and developing biomarkers that stratify biologically homogeneous populations are both necessary to realize the promise of precision medicine in ASD.
Authors: Thomas Dodsworth; David D Kim; Ric M Procyshyn; Colin J Ross; William G Honer; Alasdair M Barr Journal: Child Adolesc Psychiatry Ment Health Date: 2018-07-16 Impact factor: 3.033
Authors: Livia O Loureiro; Jennifer L Howe; Miriam S Reuter; Alana Iaboni; Kristina Calli; Delnaz Roshandel; Iva Pritišanac; Alan Moses; Julie D Forman-Kay; Brett Trost; Mehdi Zarrei; Olivia Rennie; Lynette Y S Lau; Christian R Marshall; Siddharth Srivastava; Brianna Godlewski; Elizabeth D Buttermore; Mustafa Sahin; Dean Hartley; Thomas Frazier; Jacob Vorstman; Stelios Georgiades; Suzanne M E Lewis; Peter Szatmari; Clarrisa A Lisa Bradley; Anne-Claude Tabet; Marjolaine Willems; Serge Lumbroso; Amélie Piton; James Lespinasse; Richard Delorme; Thomas Bourgeron; Evdokia Anagnostou; Stephen W Scherer Journal: NPJ Genom Med Date: 2021-11-04 Impact factor: 8.617
Authors: Maria Jimena Salcedo-Arellano; Ana Maria Cabal-Herrera; Ruchi Harendra Punatar; Courtney Jessica Clark; Christopher Allen Romney; Randi J Hagerman Journal: Neurotherapeutics Date: 2020-11-19 Impact factor: 7.620
Authors: Sara Jane Webb; Frederick Shic; Michael Murias; Catherine A Sugar; Adam J Naples; Erin Barney; Heather Borland; Gerhard Hellemann; Scott Johnson; Minah Kim; April R Levin; Maura Sabatos-DeVito; Megha Santhosh; Damla Senturk; James Dziura; Raphael A Bernier; Katarzyna Chawarska; Geraldine Dawson; Susan Faja; Shafali Jeste; James McPartland Journal: Front Integr Neurosci Date: 2020-02-07